Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study

• Published in: Translational psychiatry 2018-07, Vol.8 (1), p.130-10, Article 130
• Main Authors: Pan, Jun-Xi, Xia, Jin-Jun, Deng, Feng-Li, Liang, Wei-Wei, Wu, Jing, Yin, Bang-Min, Dong, Mei-Xue, Chen, Jian-Jun, Ye, Fei, Wang, Hai-Yang, Zheng, Peng, Xie, Peng
• Format: Article
• Language: English
• Subjects: 631/378/340; 692/53/2421; 692/699/476/1414; 82/16; 82/58; Behavioral Sciences; Biological Psychology; Biomarkers; Medicine; Medicine & Public Health; Mental depression; Metabolites; Neurosciences; Neurotransmitters; Pharmacotherapy; Plasma; Psychiatry
• ISSN: 2158-3188; 2158-3188
• DOI: 10.1038/s41398-018-0183-x

Major depressive disorder (MDD) is a debilitating psychiatric illness. However, there is currently no objective laboratory-based diagnostic tests for this disorder. Although, perturbations in multiple neurotransmitter systems have been implicated in MDD, the biochemical changes underlying the disorder remain unclear, and a comprehensive global evaluation of neurotransmitters in MDD has not yet been performed. Here, using a GC-MS coupled with LC-MS/MS-based targeted metabolomics approach, we simultaneously quantified the levels of 19 plasma metabolites involved in GABAergic, catecholaminergic, and serotonergic neurotransmitter systems in 50 first-episode, antidepressant drug-naïve MDD subjects and 50 healthy controls to identify potential metabolite biomarkers for MDD (training set). Moreover, an independent sample cohort comprising 49 MDD patients, 30 bipolar disorder (BD) patients and 40 healthy controls (testing set) was further used to validate diagnostic generalizability and specificity of these candidate biomarkers. Among the 19 plasma neurotransmitter metabolites examined, nine were significantly changed in MDD subjects. These metabolites were mainly involved in GABAergic, catecholaminergic and serotonergic systems. The GABAergic and catecholaminergic had better diagnostic value than serotonergic pathway. A panel of four candidate plasma metabolite biomarkers (GABA, dopamine, tyramine, kynurenine) could distinguish MDD subjects from health controls with an AUC of 0.968 and 0.953 in the training and testing set, respectively. Furthermore, this panel distinguished MDD subjects from BD subjects with high accuracy. This study is the first to globally evaluate multiple neurotransmitters in MDD plasma. The altered plasma neurotransmitter metabolite profile has potential differential diagnostic value for MDD.